This segment focuses on the development and commercialization of non-invasive liquid biopsy tests for cancer detection, monitoring, and treatment selection. Guardant Health's liquid biopsy technology analyzes circulating tumor DNA (ctDNA) in blood samples to identify genomic alterations that can inform clinical decision-making. Key products include Guardant360 for advanced-stage cancer and Shield for colorectal cancer screening. R&D efforts are directed towards expanding the range of detectable biomarkers, improving assay sensitivity and specificity, and developing new applications for liquid biopsy in early cancer detection and minimal residual disease monitoring. The segment leverages advanced sequencing technologies, bioinformatics, and machine learning to analyze complex genomic data and provide actionable insights to oncologists. This segment aims to improve patient outcomes by enabling earlier and more precise cancer diagnosis and treatment.

This segment provides comprehensive services to biopharmaceutical companies to support drug development and commercialization in oncology. Guardant Health partners with pharmaceutical companies to develop companion diagnostics, identify patient populations for clinical trials, and monitor treatment response. Services include clinical trial setup, monitoring, and maintenance, testing development and support, and kits fulfillment. The company's GuardantINFORM platform provides a clinical-genomic liquid biopsy dataset of advanced cancer patients, enabling researchers to identify novel drug targets and biomarkers. R&D activities focus on expanding the capabilities of the GuardantINFORM platform, developing new companion diagnostics, and improving the efficiency of clinical trial enrollment. This segment leverages Guardant Health's expertise in liquid biopsy, genomics, and data analytics to accelerate the development of new cancer therapies and improve patient outcomes.